Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Anti-Cancer Drugs

• Publication date

  2006-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/01.CAD.0000217433.48870.37PMID 16926628
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy

  2012cited by this paper
• Amplification of the epidermal‐growth‐factor‐receptor gene correlates with different growth behaviour in human glioblastoma

  2007cited by this paper
• Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric mice.

  2006cited by this paper
• Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.

  2005cited by this paper
• Molecularly targeted therapy for gastrointestinal cancer.

  2005cited by this paper
• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

  2005cited by this paper
• Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.

  2005cited by this paper
• ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors

  2005cited by this paper
• Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

  2005cited by this paper
• Tyrosine kinases as targets for cancer therapy.

  2005cited by this paper
• Intragenic EGFR and EGFR2 mutations in hepatobiliary tumors and potential role in predicting response to agents that target EGFR

  2005cited by this paper
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  2005cited by this paper
• Erlotinib in lung cancer - molecular and clinical predictors of outcome.

  2005cited by this paper
• ERBB receptors and cancer: the complexity of targeted inhibitors

  2005cited by this paper
• Epidermal growth factor receptor: a promising target in solid tumours.

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Mutation of the PIK3CA Gene in Ovarian and Breast Cancer

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Prevalence of KIT expression in human tumors.

  2004cited by this paper
• AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• High Frequency of Mutations of the PIK3CA Gene in Human Cancers

  2004cited by this paper
• Studies with ZD1839 in preclinical models.

  2003cited by this paper
• Cholangiocarcinoma: Current concepts and insights

  2003cited by this paper
• Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines.

  2003cited by this paper
• The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors.

  2003cited by this paper
• Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.

  2003cited by this paper
• Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line.

  2002cited by this paper
• Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism.

  2002cited by this paper
• Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines

  2002cited by this paper
• Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers.

  2002cited by this paper
• c‐erbB‐2 and c‐Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma

  2002cited by this paper
• Activation of BAD by Therapeutic Inhibition of Epidermal Growth Factor Receptor and Transactivation by Insulin-like Growth Factor Receptor*

  2002cited by this paper
• ERBB‐2 overexpression and cyclooxygenase‐2 up‐regulation in human cholangiocarcinoma and risk conditions

  2002cited by this paper
• The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF-kappa B. Identification of a novel receptor-tyrosine kinase signalosome.

  2001cited by this paper
• Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma.

  2001cited by this paper
• Analysis of the transcriptional program induced by Raf in epithelial cells

  2001cited by this paper
• The Epidermal Growth Factor Receptor Engages Receptor Interacting Protein and Nuclear Factor-κB (NF-κB)-inducing Kinase to Activate NF-κB

  2001cited by this paper
• Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma.

  2001cited by this paper
• Heterodimerization of the epidermal-growth-factor (EGF) receptor and ErbB2 and the affinity of EGF binding are regulated by different mechanisms.

  2001cited by this paper
• Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

  2001cited by this paper
• Epidermal Growth Factor Receptor-dependent Control of Keratinocyte Survival and Bcl-xL Expression through a MEK-dependent Pathway*

  2001cited by this paper
• Cell signaling by receptor tyrosine kinases.

  2000cited by this paper
• Akt/Protein Kinase B Isoforms Are Differentially Regulated by Epidermal Growth Factor Stimulation*

  2000cited by this paper
• Oncogenes and angiogenesis: signaling three-dimensional tumor growth.

  2000cited by this paper
• BAD Ser-155 Phosphorylation Regulates BAD/Bcl-XL Interaction and Cell Survival*

  2000cited by this paper
• Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.

  2000cited by this paper
• Epidermal growth factor receptors: critical mediators of multiple receptor pathways.

  1999cited by this paper
• Apoptosis and proliferation in relation to histopathological variables and prognosis in hepatocellular carcinoma

  1999cited by this paper
• Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway

  1999cited by this paper
• Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.

  1999cited by this paper
• In vivo evidence that caspase-3 is required for Fas-mediated apoptosis of hepatocytes.

  1999cited by this paper
• Overexpression of C‐NEU and C‐MET during rat liver cholangiocarcinogenesis: A link between biliary intestinal metaplasia and mucin‐producing cholangiocarcinoma

  1999cited by this paper
• Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis.

  1998cited by this paper
• c‐erbB‐2 protein is expressed in hepatolithiasis and cholangiocarcinoma

  1998cited by this paper
• Constitutive Activation of c-Jun N-terminal Kinase by a Mutant Epidermal Growth Factor Receptor*

  1998cited by this paper
• Constitutive Activation of Phosphatidylinositol 3-Kinase by a Naturally Occurring Mutant Epidermal Growth Factor Receptor*

  1998cited by this paper
• The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling*

  1997cited by this paper
• NEU overexpression in the furan rat model of cholangiocarcinogenesis compared with biliary ductal cell hyperplasia.

  1997cited by this paper
• ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

  1997cited by this paper
• ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.

  1996cited by this paper
• Transformational and altered signal transduction by a naturally occurring mutant EGF receptor.

  1996cited by this paper
• Prognostic value of ploidy and proliferation markers in renal cell carcinoma

  1996cited by this paper
• Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract.

  1995cited by this paper
• Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1.

  1995cited by this paper
• A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.

  1994cited by this paper
• Promoting effects of bile acid load on the occurrence of cholangiocarcinoma induced by diisopropanolnitrosamine in hamsters.

  1993cited by this paper
• Pretreatment plasma levels of fibrinopeptide‐A (FPA), D‐dimer (DD), and von Willebrand Factor (vWF) in patients with operable cervical cancer: Influence of surgical‐pathological stage, tumor size, histologic type, and lymph node status

  1993cited by this paper
• Signaling by Receptor Tyrosine Kinases

  1993cited by this paper
• Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails.

  1992cited by this paper
• Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells

  1992cited by this paper
• Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours.

  1992cited by this paper
• c-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma.

  1992cited by this paper
• Structural alterations of the epidermal growth factor receptor gene in human gliomas.

  1992cited by this paper
• Amplification of Epidermal Growth Factor Receptor Gene in Gliomas: Histopathology and Prognosis

  1992cited by this paper
• Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma.

  1990cited by this paper
• Selective amplification of the cytoplasmic domain of the epidermal growth factor receptor gene in glioblastoma multiforme.

  1988cited by this paper
• Biliary adenocarcinoma. Characterisation of three new human tumor cell lines.

  1985cited by this paper
• Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

  1984cited by this paper
• Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver.

  1975cited by this paper

• Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview

  2021cites this paper
• Liver and Bile Duct Cancer

  2020cites this paper
• Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance

  2019cites this paper
• Clinical Trial Outcomes: What Matters to Patients.

  2019cites this paper
• Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology

  2018cites this paper
• The Influence of Bisphenol A (BPA) on Neuregulin 1-Like Immunoreactive Nerve Fibers in the Wall of Porcine Uterus

  2018cites this paper
• Human epidermal growth factor receptor 2, epidermal growth factor receptor, and c-MET overexpression and survival in biliary tract cancer: A meta-analysis

  2018cites this paper
• Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancer

  2016cites this paper
• Multi-OMIC profiling of survival and metabolic signaling networks in cells subjected to photodynamic therapy

  2016cites this paper
• Enhancing photodynamic therapy of refractory solid cancers : Combining second-generation photosensitizers with multi-targeted liposomal delivery

  2015cites this paper
• Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice

  2015cites this paper
• Bile acid accelerates erbB2‐induced pro‐tumorigenic activities in biliary tract cancer

  2015cites this paper
• Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives

  2014influential citation
• Clinical Trial Outcomes part of HER 2 / neu : an increasingly important therapeutic target . Part 3 : clinical applications and investigations

  2014cites this paper
• Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan

  2014cites this paper
• HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations

  2014cites this paper
• Molecular aspects of cholangiocarcinoma

  2014cites this paper
• Optimizing oncolytic adenoviruses for treatment ofcholangiocarcinoma

  2014cites this paper
• The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines

  2012cites this paper
• Targeted therapy for biliary tract cancers

  2012cites this paper
• The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice.

  2012cites this paper
• Cholangiocarcinoma Treatment

  2012cites this paper
• Targeting EGFR in bilio-pancreatic and liver carcinoma.

  2011cites this paper
• The anti-proliferative side effects of AEE788, a tyrosine kinase inhibitor blocking both EGF- and VEGF-receptor, are liver-size-dependent after partial hepatectomy in rats

  2011cites this paper
• Dual inhibition: a novel promising pharmacological approach for different disease conditions

  2011cites this paper
• Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer

  2011cites this paper
• Molecular targeted therapy of biliary tract cancer--results of the first clinical studies.

  2010cites this paper
• Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy

  2010cites this paper
• Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas

  2010cites this paper
• Recent advances in the regulation of cholangiocarcinoma growth.

  2010cites this paper
• Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder.

  2010cites this paper
• Effects of selective COX-inhibitors and classical NSAIDs on endothelial cell proliferation and migration induced by human cholangiocarcinoma cell culture.

  2009cites this paper
• Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma

  2009cites this paper
• Targeted therapy in biliary tract cancer: 2009 update.

  2009cites this paper
• Cholangiocarcinoma.

  2008cites this paper
• Anti-Cancer Drugs 2008 Author Index to Volume 19.

  2008cites this paper
• Diagnosis and management of cholangiocarcinoma

  2008cites this paper
• Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment

  2008cites this paper
• Antagonism of the human epidermal growth factor receptor family controls disease severity in murine collagen-induced arthritis.

  2008cites this paper
• Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.

  2008cites this paper
• Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.

  2008cites this paper
• Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines.

  2008cites this paper
• Evolving therapies in the treatment of hepatocellular carcinoma

  2008cites this paper
• Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities

  2008cites this paper
• Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer.

  2008cites this paper
• Cholangiocarcinoma: Expanding the Spectrum of Risk Factors

  2008cites this paper
• Targeted medical therapy of biliary tract cancer: recent advances and future perspectives.

  2008cites this paper
• Recent advances in the development of multi-kinase inhibitors.

  2008cites this paper
• JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression?

  2007cites this paper
• HER-2/neu diagnostics in breast cancer

  2007cites this paper
• Molecular design and clinical development of VEGFR kinase inhibitors.

  2007cites this paper
• Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas: a multicenter phase II trial.

  2007cites this paper
• Establishment of a novel orthotopic xenograft model of human gallbladder carcinoma

  2007cites this paper
• Emerging drugs for biliary cancer

  2007cites this paper
• Emerging drugs for the treatment of metastatic renal cancer

  2007cites this paper
• Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach.

  2007cites this paper